PubMed Health⌕ Search

PubMed · 1409219

Venous thromboembolism.

Abstract

Pulmonary embolism is a complication of venous thrombosis. It is a major cause of morbidity and mortality, but a condition that is highly preventable and, when diagnosed, very effectively treated. Yet in the United States, more people die of pulmonary embolism each year than of AIDS. The clinician must maintain a high index of suspicion at all times in the patient at risk for this entity, keeping in mind that overall only about one-third of the patients suspected of having pulmonary embolism actually turn out to have it. A strong suspicion alone is not enough to warrant initiation of treatment, as a clinician must confirm with appropriate studies that venous thrombosis or pulmonary embolism is present. If studies of the lower extremities are negative, then a high probability ventilation perfusion scan (V/Q) or a positive pulmonary angiogram must be obtained before therapy should be considered. However, a high probability V/Q scan occurs in only 40% of patients with angiographically proven pulmonary embolism. Thus, if suspicion is high enough, do not accept a V/Q scan of 'indeterminate probability' as negative for pulmonary embolism. Even more important, though, is prevention of the disease with appropriate measures and that every individual who is at medium to high risk for development of deep venous thrombosis must have some kind of prophylaxis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E C Rosenow. 1992. Venous thromboembolism.. https://pubmed.ncbi.nlm.nih.gov/1409219/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Thermally reversible pluronic/heparin nanocapsules exhibiting 1000-fold volume transition.

Novel Pluronic/heparin composite nanocapsules that exhibit a thermally responsible swelling and deswelling behavior were synthesized. Pluronic F-127 preactivated with p-nitrophenyl chloroformate at its two terminal hydroxyl groups was dissolved in a methylene chloride phase. The organic phase was dispersed in an aqueous phase containing heparin. At an organic/aqueous interface, Pluronic-cross-linked heparin nanocapsules were produced. They exhibited a 1000-fold volume transition (ca. 336 nm at 25 degrees C; ca. 32 nm at 37 degrees C), and a reversible swelling and deswelling behavior when the temperature was cycled between 20 and 37 degrees C. The reversible volume transition of Pluronic nanocapsules was caused by micellization and demicellization of cross-linked Pluronic polymer chains within the nanocapsule structure in response to temperature. The morphological characters were investigated with transmission electron microscopy and small angle neutron scattering. Pluronic/heparin nanocapsules had an aqueous fluid-filled hollow interior with a surrounding shell layer below the critical temperature, but they became a collapsed core/shell structure similar to that of Pluronic micelles above it.

Heparin↗